Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure
RETRO
1 other identifier
interventional
20
1 country
1
Brief Summary
In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage HF management.
- The study team hypothesize that older HF patients will be able to use IMT safely, reliably, and effectively in a 12-week home-based training regimen.
- The study team hypothesize that physical function (sit to stand, gait speed, grip strength), respiratory/pulmonary function, self-efficacy, fatigue and quality of life will increase among older HF patients randomized IMT versus those randomized to usual care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jun 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 22, 2024
CompletedStudy Start
First participant enrolled
June 30, 2024
CompletedFirst Posted
Study publicly available on registry
August 28, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 28, 2025
CompletedResults Posted
Study results publicly available
July 17, 2026
CompletedJuly 17, 2026
July 1, 2026
8 months
February 22, 2024
February 27, 2026
July 15, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Completion of 3-month Assessment
The number of participants who complete the 3-month assessment is used as a measure of intervention feasibility. Completion of this assessment indicates the feasibility of retaining participants in the study throughout the 3-month intervention period.
3-month
Secondary Outcomes (7)
Change in MIP (Maximum Inspiratory Pressure)
Baseline to 3-months
Change in Sit to Stand Time
Baseline to 3-months
Change in Gait Speed
Baseline to 3-month
Change in the Sullivan Self-Efficacy to Maintain Function Scale
Baseline to 3-month
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ): Quality of Life Score
Baseline to 3-month
- +2 more secondary outcomes
Study Arms (2)
Standard of Care
ACTIVE COMPARATORParticipants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
IMT Group: Inspiratory Muscle Training (IMT)
EXPERIMENTALIMT exercise sessions addition to standard of care.
Interventions
IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.
Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
Eligibility Criteria
You may qualify if:
- Patients with Advanced Heart Failure (HFrEF or HFpEF), with NYHA class II, III, or IV despite a minimum of
- weeks of treatment
- Age \>70 years
- Male and Female
- Optimal therapy according to AHA/ACC and HFSA HF guidelines
You may not qualify if:
- Patients living in an institutional setting (e.g., skilled nursing home) during the intended period of this study.
- Major cardiovascular event or procedure within the prior 6 weeks.
- HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction). If valve replacement has been performed, the participant may not be enrolled for 12 months after this procedure.
- Dementia
- Severe COPD (FEV1\<50%), PVD, and/or Anemia
- End-stage malignancy
- Severe valvular heart disease
- Psychiatric hospitalization within the last 3 months
- Chronic ETOH or drug dependency.
- We will exclude all of the following special populations:
- Adults unable to consent
- Individuals who are not yet adults (infants, children, teenagers)
- Pregnant women
- Prisoners
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pittsburghlead
- The Pittsburgh Foundationcollaborator
Study Sites (1)
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Results Point of Contact
- Title
- Daniel E. Forman, M.D.
- Organization
- University of Pittsburgh
Study Officials
- PRINCIPAL INVESTIGATOR
Daniel E. Forman, M.D
University of Pittsburgh
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Investigator, Outcomes assessor
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
February 22, 2024
First Posted
August 28, 2024
Study Start
June 30, 2024
Primary Completion
February 28, 2025
Study Completion
February 28, 2025
Last Updated
July 17, 2026
Results First Posted
July 17, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- Data will be available one year after study is closed.
- Access Criteria
- Per PI discretion
Hope to publish results of this pilot study.